Objective To develop a process which assists pharmacists in oncology order review, patient assessment, drug therapy monitoring, and documentation and evaluate whether it is useful in practice.
Methods A process called the anDROIDs (Appendix A) is discussed. The acronym represents Antineoplastic Data Collection, Review of Systems, Oncology Target, Identification of drug-related problems, and Documentation System. A tool representing the process was created and introduced to a focus group in an oncology pharmacy workshop. Participants’ responses were measured using pre- and post-workshop assessments.
Results. The focus group had positive responses in the post-workshop assessment compared to pre-workshop data. Participants found the anDROIDs tool to be easy to use and planned to incorporate it into their pharmacy practice.
Conclusion The anDROIDs tool may have potential application in oncology pharmacy and can be modified to other pharmacy practice settings.
Schuster B, Ponting A.Jim Keston. PHARMALearn. Continuing Pharmacy Education, University of Alberta, 1997.
2.
Fischer DS, Knobf MT, Durivage HJ.Assessment and management of organ system toxicity. In Baxter S ed. The cancer chemotherapy handbook, fifth edition. St. Louis, MO: Mosby-Yearbook Inc., 1997: 475-545.
3.
Gurney H.Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. JCO1996; 14: 2590-2611.
4.
Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Hoff DV, Wasserman TH, Winer EP, Pfister DG, for the American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol1999; 17: 3333-3355.
5.
Strand LM, Cipolle RJ, Morley PC.Documenting the clinical pharmacist’s activities: back to basics. Drug Intell Clin Pharm1988; 22: 63-66.
6.
Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsan GD.Drug-related problems: their structure and function. DICP1990 Nov; 24: 1093-1097.
7.
Hepler CD, Strand LM.Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm1990; 47: 533-543.
8.
Hutcherson DA, Gammon DC.Preventing errors with antineoplastic agents: a pharmacist’s approach. Hosp Pharm1997; 32: 190-209.
9.
An information paper on documentation of pharmaceutical care in the health care record. Canadian Society of Hospital Pharmacists Website. 1996. Available at: http://cshp.ca/products/products.html. Accessed Sept 30, 2002.
10.
Evans WK.Acronyms in cancer chemotherapy, seventh edition. University of Ottawa, ON, 1999.
11.
Canal P, Chatelut E, Guichard S.Practical treatment guide for dose individualisation in cancer chemo-therapy. Drugs1998; 56: 1019-1038.
12.
Wiegand A.Cytostatics dosage in case of impaired renal function. In: ISOPP. Quality standards for the oncology pharmacy service. Germany: IFAHS;2000: 127-139.
13.
Kintzel PE, Dorr RT.Anticancer drug renal toxiiiicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev1995; 21: 33-64.
14.
Finley RS, Balmer C.Optimizing chemotherapy outcomes. In Finley RS, Balmer C eds. Concepts in oncology therapeutics, second edition. Bethesda, MD: ASHP, 1998: 81-97.
15.
Donelli MG, Zucchetti M, Munzone E, D’Incalci M, Crosignani A.Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer1998; 34: 33-46.
16.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG, for the American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol1999; 17: 2971-2994.
17.
Kapty D, Chow L, Anderson K, Barnett J, Chambers C, Esau R, McBride J, Moore M, O’Brien R, Walisser S, Hamilton D, Kim-Sing C, Louie S, Nakashima L, Oliver J, Plenderleith I, Pritchard S, Rayner H, Zaremba C.Cancer drug manual, second edition. British Columbia Cancer Agency, Division of Pharmacy, 1994.
